• SPX
  • $5,764.08
  • 0.9 %
  • $51.39
  • DJI
  • $42,096.24
  • 0.72 %
  • $301.64
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,178.59
  • -0.07 %
  • -$5.65
  • IXIC
  • $18,387.44
  • 1.14 %
  • $207.46
TG Therapeutics, Inc. (TGTX) Stock Price, News & Analysis

TG Therapeutics, Inc. (TGTX) Stock Price, News & Analysis

Currency in USD Disclaimer

$24.39

$0.03

(0.1%)

Day's range
$23.6
Day's range
$24.67
50-day range
$21.11
Day's range
$26.99
  • Country: US
  • ISIN: US88322Q1085
52 wk range
$9.81
Day's range
$26.99
  • CEO: Mr. Michael S. Weiss Esq.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 7.23
  • Piotroski Score 6.00
  • Grade Buy
  • Symbol (TGTX)
  • Company TG Therapeutics, Inc.
  • Price $24.39
  • Changes Percentage (0.1%)
  • Change $0.03
  • Day Low $23.60
  • Day High $24.67
  • Year High $26.99

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/04/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $23.00
  • High Stock Price Target $49.00
  • Low Stock Price Target $16.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.30
  • Trailing P/E Ratio 52.83
  • Forward P/E Ratio 52.83
  • P/E Growth 52.83
  • Net Income $12.67 M

Income Statement

Quarterly

Annual

Latest News of TGTX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.